Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
40.81-3.73 (-8.37%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close44.54
Bid38.34 x 100
Ask41.80 x 1000
Day's Range40.02 - 45.40
52wk Range8.00 - 63.73
1y Target EstN/A
Market Cap2.16B
P/E Ratio (ttm)-7.62
Avg Vol (3m)4,168,232
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com16 hours ago

    Why Sarepta is Sinking

    Shares of Sarepta Therapeutics (SRPT) are getting smacked today despite reporting a smaller-than-expected loss. Leerink's Joseph Schwartz and Dae Gon Ha point to Sarepta's inability to "quantify the initial demand" for its recently approved Duchenne Muscular Dystrophy treatment: Sarepta is pleased with the response to Exondys 51 in the marketplace overall, but at just 23 days since approval, believes it is too early to provide metrics or guidance. Sarepta expects to quantify the initial demand/uptake it is seeing after the first full quarter of sales in early January.

  • Thomson Reuters StreetEvents17 hours ago

    Edited Transcript of SRPT earnings conference call or presentation 27-Oct-16 12:00pm GMT

    Q3 2016 Sarepta Therapeutics Inc Earnings Call

  • Associated Press22 hours ago

    Sarepta Therapeutics reports 3Q loss

    The Cambridge, Massachusetts-based company said it had a loss of $1.18 per share. Losses, adjusted for stock option expense and non-recurring costs, came to 95 cents per share. The results exceeded Wall ...